Menu Search
Equities

Sarepta Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
AB3A:DEU

Sarepta Therapeutics Inc

Actions
  • Price (EUR)15.53
  • Today's Change-0.975 / -5.91%
  • Shares traded1.64k
  • 1 Year change-88.88%
  • Beta0.4548
Data delayed at least 15 minutes, as of Jul 11 2025.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.

  • Revenue in USD (TTM)2.23bn
  • Net income in USD-248.39m
  • Incorporated2013
  • Employees1.37k
  • Location
    Sarepta Therapeutics Inc215 First Street, Suite 415CAMBRIDGE 02142United StatesUSA
  • Phone+1 (617) 274-4000
  • Fax+1 (302) 636-5454
  • Websitehttps://www.sarepta.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.